title: Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device.
abstract: The presentation, cardiac anatomy and utility of programmed ventricular stimulation in seven patients with sustained ventricular tachycardia associated with sarcoidosis are described. The mean patient age was 38 +/- 8 years. Pulmonary involvement was apparent in three patients and no systemic manifestations of sarcoidosis were present in one patient. All patients had electrocardiographic abnormalities at rest and six had a left ventricular ejection fraction less than 45%. All seven patients had left ventricular wall motion abnormalities and five had mitral valve dysfunction. Sustained ventricular tachycardia was easily induced in all patients. Spontaneous sustained ventricular tachycardia was not prevented with corticosteroid administration. Despite antiarrhythmic drug therapy, two patients had sudden cardiac death and an additional four had recurrence of ventricular tachycardia. Four patients had an automatic cardioverter-defibrillator implanted and received drug therapy; all four received appropriate shocks. This report represents the largest descriptive series of consecutive patients with sustained ventricular tachycardia associated with sarcoidosis. Antiarrhythmic drug therapy of ventricular tachycardia in patients with sarcoidosis, even when guided with programmed ventricular stimulation, is associated with a high rate of arrhythmia recurrence or sudden death, or both. Thus, implantation of an automatic antitachycardia device (cardioverter-defibrillator) should be considered as primary therapy in such patients. Furthermore, sarcoidosis should be excluded, with Kveim skin testing if necessary, in any patient with sustained ventricular tachycardia of unknown origin.
authors.affiliation: Department of Medicine, Mount Sinai School of Medicine, City University of New York, New York 10029.
authors.forename: S L
authors.initials: SL
authors.lastname: Winters
authors.forename: M
authors.initials: M
authors.lastname: Cohen
authors.forename: S
authors.initials: S
authors.lastname: Greenberg
authors.forename: B
authors.initials: B
authors.lastname: Stein
authors.forename: J
authors.initials: J
authors.lastname: Curwin
authors.forename: E
authors.initials: E
authors.lastname: Pe
authors.forename: J A
authors.initials: JA
authors.lastname: Gomes
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002304:Cardiac Pacing, Artificial; D009202:Cardiomyopathies / Q000150:complications*; D003645:Death, Sudden / Q000453:epidemiology; D004554:Electric Countershock / Q000295:instrumentation*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D019736:Prostheses and Implants; D012307:Risk Factors; D012507:Sarcoidosis / Q000150:complications*; D013610:Tachycardia / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy
chemical_list: D000889:Anti-Arrhythmia Agents; D011241:Prednisone